ArticleHepatology international2013
Angiogenesis: a phenomenon which aggravates chronic liver disease progression.
Article in Hepatology international, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 34 citations in OpenAlex.
- Beyond VEGF: AEG-1/MTDH as a Systems-Level Orchestrator of Angiogenesis in Hepatocellular Carcinoma.Cells · 2026Review
- Synthesis and application of encapsulated Bifidobacterium Longum for mitigation of liver fibrosis via modulation of oxidative stress and inflammation in BDL rat model.World journal of microbiology & biotechnology · 2026Article
- Molecular docking andRSC advances · 2024Article
- Isolation and purification of polysaccharides fromFrontiers in pharmacology · 2024Article
- Portosystemic shunt placement reveals blood signatures for the development of hepatic encephalopathy through mass spectrometry.Nature communications · 2023Article
- Anti-Angiogenic Effects of Natural Compounds in Diet-Associated Hepatic Inflammation.Nutrients · 2023Review
- Article
- Chronic Inflammatory and Immune Microenvironment Promote Hepatocellular Carcinoma Evolution.Journal of inflammation research · 2023Review
- Liver fibrosis: Pathophysiology and clinical implications.WIREs mechanisms of disease · 2021Review
- Article
- Mechanisms of liver fibrosis and its role in liver cancer.Experimental biology and medicine (Maywood, N.J.) · 2020Review
- Natural History of Nonalcoholic Fatty Liver Disease: Implications for Clinical Practice and an Individualized Approach.Canadian journal of gastroenterology & hepatology · 2020Review
- Dabigatran Reduces Liver Fibrosis in Thioacetamide-Injured Rats.Digestive diseases and sciences · 2019Article
- Article
- Underrated enemy - from nonalcoholic fatty liver disease to cancers of the gastrointestinal tract.Clinical and experimental hepatology · 2018Review
- Serum levels of vascular endothelial growth factor in non-alcoholic fatty liver disease.Annals of gastroenterology · 2017Article
- Berberine Inhibition of Fibrogenesis in a Rat Model of Liver Fibrosis and in Hepatic Stellate Cells.Evidence-based complementary and alternative medicine : eCAM · 2016Article
- Neuropilins and liver.World journal of gastroenterology · 2015Review
- Angiogenesis and liver fibrosis.World journal of hepatology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It has become increasingly clear that angiogenesis occurring during chronic wound healing and fibrogenesis provides a key contribution to disease progression and complications. The association of fibrogenesis and angiogenesis should be regarded as crucial in the modern evaluation of liver disease progression and in the search for therapeutic targets. Physiological hepatic angiogenesis occurs during liver regeneration, contributing to the formation of new functional sinusoids. Pathological angiogenesis in liver is characterized by intrahepatic vascular remodeling with capillarization of the sinusoids and development of intrahepatic shunts, which lead to increased hepatic resistance and decreased effective hepatocyte perfusion. The problem of angiogenesis in chronic hepatitis C and nonalcoholic fatty liver disease has not been fully resolved. This manuscript briefly describes pathogenesis of new blood vessel formation in chronic hepatitis and potential role of angiogenesis in disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.